This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure

This study has been completed.
Information provided by (Responsible Party):
Medtronic - MITG Identifier:
First received: July 22, 2010
Last updated: September 30, 2014
Last verified: September 2014

Trial Objectives

The primary objectives of this clinical trial are to estimate the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set:

overall performance defined by the successful creation of a normal staple line safety as measured by the 30 day incidence of adverse events.

Condition Intervention
Hemorrhoid Device: Hemorrhoidopexy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center Investigation Of The Safety And Performance Of The Covidien EEA™ Hemorrhoid And Prolapse Stapling Set With DST Series™ Technology Im A Hemorrhoidopexy Procedure

Resource links provided by NLM:

Further study details as provided by Medtronic - MITG:

Primary Outcome Measures:
  • Uneventful Creation of a Functional Staple Line at First Firing of Device [ Time Frame: about 20 minutes for procedure ]
    Successful creation of staple line at first firing of device during hemorrhoidopexy

Secondary Outcome Measures:
  • OR Time [ Time Frame: Day 0 - Time of stop minus time of start ]
    Duration of procedure

  • Intra-Operative Bleeding Requiring Intervention [ Time Frame: Day 0 - time of surgery ]
    Incidence of intervention for intra-operative staple-line bleeding

  • Length of Stay [ Time Frame: Day 0, time of discharge minus time of admission ]
    length of time between time of admission and time of discharge

  • Time to Return to Normal Activity [ Time Frame: 30 days post op ]
  • Incidence of Stapler Malfunction or Misfires [ Time Frame: about 20 minutes for procedure ]
  • Post Operative Pain [ Time Frame: baseline, 30 days post op ]
    Post operative pain measured by 11 point visual analog scale, measured as change from baseline The scale range is 0-10, where 0 = no pain and 10 = worst possible pain

  • Quality of Life, Physical Component [ Time Frame: baseline, 30 days post op ]
    Physical component score SF36 scale measured as change from baseline the scoring ranges from 0 to 100 with 0 = unable to do anything while 100 = capable of physical activity without limitation

  • Quality of Life, Mental Component [ Time Frame: Baseline, 30 days post op ]
    quality of life, SF36 measure as change from baseline the scoring ranges from 0 to 100 with 0 = complete mental activity limitation; while 100 = capable of mental activity without limitation

Enrollment: 27
Study Start Date: July 2010
Study Completion Date: July 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HEEA Stapler
hemorrhoidopexy using Covidien EEA Hemorrhoid and Prolapse Stapling Set
Device: Hemorrhoidopexy
Other Name: Covidien EEA Hemorrhoid and Prolapse Stapling set


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to understand and sign Informed Consent Form
  • The participant must be 18-80 years of age.
  • The participant has (symptomatic) Grade 2-4 Hemorrhoids and is eligible for stapled hemorrhoidopexy.

Exclusion Criteria:

  • The procedure is needed as revision hemorrhoid surgery.
  • The participant is pregnant.
  • The participant has an active or a history of infection requiring antibiotics at the intended operative site within thirty (30) days prior to the planned surgery date.
  • The participant is unable or unwilling to comply with the study requirements, follow-up schedule.
  • The participant has a history of drug or alcohol abuse.
  • The participant has a history of venous thrombosis or pulmonary embolism.
  • The participant has a history of coagulopathy.
  • The participant is taking aspirin, anti-coagulation and/or anti platelet therapies (e.g.: Warfarin, Levonox) within the last 7 days prior to the planned surgery date
  • The participant has a history of fecal incontinence.
  • The participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01169311

United States, New York
Weill Cornell Medical Center
New York, New York, United States, 10065
Sponsors and Collaborators
Medtronic - MITG
Principal Investigator: Sang Lee, M.D. Weill Medical College of Cornell University
  More Information

Responsible Party: Medtronic - MITG Identifier: NCT01169311     History of Changes
Other Study ID Numbers: COVHEPH0021
Study First Received: July 22, 2010
Results First Received: January 17, 2014
Last Updated: September 30, 2014

Keywords provided by Medtronic - MITG:
grade II, III, IV

Additional relevant MeSH terms:
Pathological Conditions, Anatomical
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on September 19, 2017